Lakefront Biotherapeutics NV 2020 SR
The report highlights Galapagos' commitment to CSR through four material pillars: improving lives, employee well-being, ethical business, and environmental care. In 2020, the company achieved regulatory approval for filgotinib in Europe and Japan and invested 524 million Euros in R&D. The workforce grew to 1,489 employees representing 50 nationalities, achieving 50% female representation on the supervisory board. Galapagos also aligned its strategy with eight UN Sustainable Development Goals and implemented an Animal Welfare Committee to oversee ethical research practices.
Company: Lakefront Biotherapeutics NV
Sector: Professional & technical services
Country: Belgium
Year: 2020
Type: SR
Pages: 27
Back to company
Lakefront Biotherapeutics NV
CSR Report
The report highlights Galapagos' commitment to CSR through four material pillars: improving lives, employee well-being, ethical business, and environmental care. In 2020, the company achieved regulatory approval for filgotinib in Europe and Japan and invested 524 million Euros in R&D. The workforce grew to 1,489 employees representing 50 nationalities, achieving 50% female representation on the supervisory board. Galapagos also aligned its strategy with eight UN Sustainable Development Goals and implemented an Animal Welfare Committee to oversee ethical research practices.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Employees